Newron Pharmaceuticals S.p.A. NP5.F Stock
Newron Pharmaceuticals S.p.A. Price Chart
Newron Pharmaceuticals S.p.A. NP5.F Financial and Trading Overview
| Newron Pharmaceuticals S.p.A. stock price | 10.42 EUR |
| Previous Close | 4.3 EUR |
| Open | 4.2 EUR |
| Bid | 0 EUR x 0 |
| Ask | 0 EUR x 0 |
| Day's Range | 4.2 - 4.24 EUR |
| 52 Week Range | 1 - 9 EUR |
| Volume | 700 EUR |
| Avg. Volume | 605 EUR |
| Market Cap | 78.19M EUR |
| Beta (5Y Monthly) | 0.8318 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.91 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
NP5.F Valuation Measures
| Enterprise Value | 98.91M EUR |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 12.830834 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 16.231 |
| Enterprise Value/EBITDA | -7.456 |
Trading Information
Newron Pharmaceuticals S.p.A. Stock Price History
| Beta (5Y Monthly) | 0.8318 |
| 52-Week Change | 197.90% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 9 EUR |
| 52 Week Low | 1 EUR |
| 50-Day Moving Average | 4.77 EUR |
| 200-Day Moving Average | 3.1 EUR |
NP5.F Share Statistics
| Avg. Volume (3 month) | 605 EUR |
| Avg. Daily Volume (10-Days) | 967 EUR |
| Shares Outstanding | 17.85M |
| Float | 16.95M |
| Short Ratio | N/A |
| % Held by Insiders | 5.01% |
| % Held by Institutions | 7.43% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -287.053% |
| Operating Margin (ttm) | -218.27% |
| Gross Margin | 100.00% |
| EBITDA Margin | -217.67% |
Management Effectiveness
| Return on Assets (ttm) | -18.96% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 6.09M EUR |
| Revenue Per Share (ttm) | 0.34 EUR |
| Quarterly Revenue Growth (yoy) | 5.60% |
| Gross Profit (ttm) | 6.09M EUR |
| EBITDA | -13265000 EUR |
| Net Income Avi to Common (ttm) | -17493000 EUR |
| Diluted EPS (ttm) | -1.03 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 22.77M EUR |
| Total Cash Per Share (mrq) | 1.28 EUR |
| Total Debt (mrq) | 45.66M EUR |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 5.652 |
| Book Value Per Share (mrq) | -0.786 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -11092000 EUR |
| Levered Free Cash Flow (ttm) | -9637625 EUR |
Profile of Newron Pharmaceuticals S.p.A.
| Country | Germany |
| State | MI |
| City | Bresso |
| Address | Via Antonio Meucci 3 |
| ZIP | 20091 |
| Phone | 39 02 610 3461 |
| Website | https://www.newron.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 23 |
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The company's product pipeline includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. In addition, it has a strategic partnership with Zambon for the commercialization of safinamide; and license agreement with Meiji Seika Pharma Co., Ltd., for research, develop, manufacture, and marketing of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy.
Q&A For Newron Pharmaceuticals S.p.A. Stock
What is a current NP5.F stock price?
Newron Pharmaceuticals S.p.A. NP5.F stock price today per share is 10.42 EUR.
How to purchase Newron Pharmaceuticals S.p.A. stock?
You can buy NP5.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Newron Pharmaceuticals S.p.A.?
The stock symbol or ticker of Newron Pharmaceuticals S.p.A. is NP5.F.
Which industry does the Newron Pharmaceuticals S.p.A. company belong to?
The Newron Pharmaceuticals S.p.A. industry is Biotechnology.
How many shares does Newron Pharmaceuticals S.p.A. have in circulation?
The max supply of Newron Pharmaceuticals S.p.A. shares is 18.93M.
What is Newron Pharmaceuticals S.p.A. Price to Earnings Ratio (PE Ratio)?
Newron Pharmaceuticals S.p.A. PE Ratio is now.
What was Newron Pharmaceuticals S.p.A. earnings per share over the trailing 12 months (TTM)?
Newron Pharmaceuticals S.p.A. EPS is -0.91 EUR over the trailing 12 months.
Which sector does the Newron Pharmaceuticals S.p.A. company belong to?
The Newron Pharmaceuticals S.p.A. sector is Healthcare.